Join our daily newsletter At The Bell to receive exclusive market insights
- Incannex Healthcare (IHL) commences its phase one human clinical trial to assess the safety of IHL-675A soft gel capsules on healthy volunteers
- The company’s drug has the potential to prevent and treat inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel disease
- The aim of the trial is to demonstrate there are no or minimal side effects associated with the combination of Cannabidiol and Hydroxychloroquine
- If successful, these results will form part of the food and drug administration investigational new drug application
- Just before the market opens for the day, IHL is trading at 25.5 cents per share
Incannex Healthcare (IHL) has commenced its phase one human clinical trial to assess the safety of IHL-675A soft gel capsules.
The treatment has the potential to be a multi-use drug candidate for the prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel disease.
A total of 36 healthy volunteers will take part in this trial and they will be evenly divided across the three arms of the trial.
The aim of the trial is to demonstrate there are no or minimal side effects associated with the combination of Cannabidiol (CBD) and Hydroxychloroquine (HCQ).
HCQ is a disease-modifying anti-rheumatic drug that regulates the activity of the immune system. It can modify the underlying disease process, rather than just treating the symptoms.
If successful, these results will form part of the food and drug administration investigational new drug application.
IHL will conduct the study in South Australia at CMAX’s clinical research facility.
The market for treatments for inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel disease is exceeding US$125 billion (around A$169 billion) per annum.
Just before the market opened for the day, IHL was trading at 25.5 cents per share.
